Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...
Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...
Well-known industry author and instructor Jim Johnson is offering a new video for technicians who want to sharpen their troubleshooting skills. "This HVAC training video program, is available in DVD ...
Crowbar circuits have long been the go-to safeguard against overvoltage conditions, prized for their simplicity and ...
"Hydraulic Schematics and Basic Circuit Design" provides an overview of basic hydraulic circuit configurations and the standard fluid symbols in fluid schematic diagrams. A hydraulic schematic diagram ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
As of 10:47:05 AM EST. Market Open. BMY: Risk or rebound? News headlines Bristol Myers Squibb (BMY) is navigating a dynamic landscape with recent developments in drug pricing agreements and notable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback